Magnesium sulphate
magnesium sulphate pharmacology mechanism indications
magnesium sulphate eclampsia preeclampsia dosing protocol
| Property | Detail |
|---|---|
| Class | Electrolyte / CNS depressant / Anticonvulsant |
| Mechanism | Blocks NMDA receptors; antagonizes Ca²⁺ at cell membranes; slows neuromuscular transmission |
| Route | IV, IM, oral, topical |
| Elimination | Renal (dose reduction in renal impairment) |
| Monitoring | Serum Mg²⁺, deep tendon reflexes (DTR), respiratory rate, urine output |
| Indication | Dose (typical) |
|---|---|
| Severe acute asthma (refractory) | 1.2–2 g IV over 20 min |
| Hypomagnesaemia | 1–2 g IV replacement |
| Preterm labour tocolysis | 4–6 g IV load, then 1–2 g/h |
| Neuroprotection in preterm birth (<32 weeks) | 4 g IV load |
| Constipation / bowel prep | Oral (saline laxative effect) |
| Serum Mg²⁺ (mmol/L) | Effect |
|---|---|
| 2–3.5 | Therapeutic range (eclampsia) |
| 3.5–5 | Loss of deep tendon reflexes |
| 5–7.5 | Respiratory paralysis |
| >7.5 | Cardiac arrest |